Cited 0 time in
내시경적 점막하 박리술 후 Pantoprazole 주사와 경구 Lansoprazole의 위액 산도를 통한 출혈 예방 효과 비교
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 이창근 | - |
| dc.contributor.author | 임윤정 | - |
| dc.contributor.author | 한석재 | - |
| dc.contributor.author | 강현우 | - |
| dc.contributor.author | 김재학 | - |
| dc.contributor.author | 이준규 | - |
| dc.contributor.author | 고문수 | - |
| dc.contributor.author | 이진호 | - |
| dc.contributor.author | 양창헌 | - |
| dc.date.accessioned | 2024-08-08T05:01:40Z | - |
| dc.date.available | 2024-08-08T05:01:40Z | - |
| dc.date.issued | 2014-06 | - |
| dc.identifier.issn | 1738-3331 | - |
| dc.identifier.issn | 2671-826X | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/18507 | - |
| dc.description.abstract | Background/Aims: Proton pump inhibitor (PPI) is generally prescribed to prevent post endoscopic submucosal dissection (ESD) bleeding. However, there was no consensus about the effectiveness of intravenous (IV) or oral PPI. We conducted this investigation to evaluate whether oral PPI can be also safely and effectively used to prevent post-ESD bleeding by measurement of intragastric pH. Materials and Methods: Patients were assigned in the fixed order to IV pantoprazole by 40 mg every 12 hours and oral lansoprazole fast disintegrating tablet (LFDT) by 30 mg every 8 hours. We checked intragastric pH and hemoglobin (Hb) levels at pre and post-ESD procedure. Results: A total of 10 patients (LFDT group: 6 patients, IV pantoprazole group: 4 patients) were included. There was no difference of baseline Hb level between two groups (LFDT, 14.38±0.46 mg/dL; IV pantoprazole, 13.85±0.83 mg/dL; P=0.18). After 24 hours, change of Hb level was not different between LFDT (0.95±0.30 mg/dL) and IV pantoprazole group (0.98±0.45 mg/dL; P=0.96). Baseline intragastric pH was 3.72±0.19 with LFDT and 4.31±0.41 with IV pantoprazole group (P=0.18). After 24 hours, there was no significant difference of the extent of pH increase between LFDT (2.38±0.28) and IV pantoprazole group (2.17±0.21; P=0.60). Conclusions: There was no difference in both the increase of post-24 hour intragastric pH and decrease of post-24 hour Hb between LFDT and IV pantoprazole group. Oral PPI regimen may be able to replace IV PPI therapy for the prevention of post-ESD bleeding and LFDT might be superior to IV PPIs in the aspect of cost-effectiveness. | - |
| dc.format.extent | 5 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | 대한상부위장관ㆍ헬리코박터학회 | - |
| dc.title | 내시경적 점막하 박리술 후 Pantoprazole 주사와 경구 Lansoprazole의 위액 산도를 통한 출혈 예방 효과 비교 | - |
| dc.title.alternative | Comparison between Intravenous Pantoprazole and Oral Lansoprazole about the Prevention against Bleeding after Endoscopic Submucosal Dissection | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.7704/kjhugr.2014.14.2.103 | - |
| dc.identifier.bibliographicCitation | Korean Journal of Helicobacter Upper Gastrointestinal Research, v.14, no.2, pp 103 - 107 | - |
| dc.citation.title | Korean Journal of Helicobacter Upper Gastrointestinal Research | - |
| dc.citation.volume | 14 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 103 | - |
| dc.citation.endPage | 107 | - |
| dc.identifier.kciid | ART001960490 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | kciCandi | - |
| dc.subject.keywordAuthor | Endoscopic | - |
| dc.subject.keywordAuthor | Submucosal | - |
| dc.subject.keywordAuthor | Dissection | - |
| dc.subject.keywordAuthor | Bleeding | - |
| dc.subject.keywordAuthor | Proton pump inhibitors | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
